Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Standard Biotools (LAB) EBITDA Margin (2016 - 2026)

Standard Biotools has reported EBITDA Margin over the past 16 years, most recently at 103.57% for Q4 2025.

  • Quarterly EBITDA Margin fell 43622.0% to 103.57% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 109.77% through Dec 2025, down 7955.0% year-over-year, with the annual reading at 129.2% for FY2025, 10834.0% down from the prior year.
  • EBITDA Margin was 103.57% for Q4 2025 at Standard Biotools, up from 168.46% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 332.65% in Q4 2024 and troughed at 205.37% in Q2 2022.
  • The 5-year median for EBITDA Margin is 83.46% (2023), against an average of 78.85%.
  • Year-over-year, EBITDA Margin soared 42309bps in 2021 and then crashed -43622bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 68.8% in 2021, then dropped by -14bps to 78.13% in 2022, then grew by 3bps to 75.87% in 2023, then soared by 538bps to 332.65% in 2024, then plummeted by -131bps to 103.57% in 2025.
  • Per Business Quant, the three most recent readings for LAB's EBITDA Margin are 103.57% (Q4 2025), 168.46% (Q3 2025), and 118.08% (Q2 2025).